Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 12/20 | 0.54 |
| ▸ | JAK3 | P52333 | 9/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421973 | 1.00 | JAK2 (0.54) | JAK2JAK3MAPK1MAPTNTRK1 | |
| SCHEMBL2161854 | 0.87 | JAK2 (0.54) | JAK2JAK3MAPK1MAPTNTRK1 | |
| SCHEMBL4419211 | 0.87 | JAK2 (0.54) | JAK2JAK3MAPK1MAPTNTRK1 | |
| SCHEMBL2162010 | 0.81 | JAK2 (0.57) | JAK2JAK3MAPTNTRK1 | |
| SCHEMBL1396515 | 0.81 | JAK2 (0.57) | JAK2JAK3MAPTNTRK1 | |
| SCHEMBL3671795 | 0.81 | JAK2 (0.65) | JAK2JAK3NTRK1KCNH2 | |
| SCHEMBL2338534 | 0.81 | JAK2 (0.65) | JAK2JAK3NTRK1KCNH2 | |
| SCHEMBL2332818 | 0.81 | JAK2 (0.65) | JAK2JAK3MAPTNTRK1KCNH2 | |
| SCHEMBL2160983 | 0.80 | JAK2 (0.57) | JAK2JAK3NTRK1 | |
| SCHEMBL4571027 | 0.79 | JAK2 (0.74) | JAK2JAK3MAPTNTRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-07-28 | — | — | US | disclosed |
| WO-2009150462-A1 | TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183954-A1 | TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS | THPO, MPL, MCL1 | JAK2 6/4885JAK3 188/4885MAPK1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.